nodes	percent_of_prediction	percent_of_DWPC	metapath
Melphalan—Ureteric obstruction—Epirubicin—liver cancer	0.0235	0.0301	CcSEcCtD
Melphalan—Chlorambucil—GSTP1—liver cancer	0.0229	0.37	CrCbGaD
Melphalan—L-Tyrosine—TAT—liver cancer	0.0227	0.367	CrCbGaD
Melphalan—Ureteric obstruction—Doxorubicin—liver cancer	0.0218	0.0279	CcSEcCtD
Melphalan—Interstitial pneumonia—Sorafenib—liver cancer	0.0216	0.0277	CcSEcCtD
Melphalan—Respiratory distress—Sorafenib—liver cancer	0.0164	0.021	CcSEcCtD
Melphalan—Interstitial lung disease—Sorafenib—liver cancer	0.0148	0.0189	CcSEcCtD
Melphalan—Leukaemia—Epirubicin—liver cancer	0.0143	0.0183	CcSEcCtD
Melphalan—Acute leukaemia—Epirubicin—liver cancer	0.0135	0.0173	CcSEcCtD
Melphalan—Leukaemia—Doxorubicin—liver cancer	0.0133	0.017	CcSEcCtD
Melphalan—L-Phenylalanine—TAT—liver cancer	0.0132	0.213	CrCbGaD
Melphalan—Acute leukaemia—Doxorubicin—liver cancer	0.0125	0.016	CcSEcCtD
Melphalan—Neoplasm malignant—Sorafenib—liver cancer	0.0122	0.0157	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—IL12A—liver cancer	0.0121	0.077	CbGpPWpGaD
Melphalan—Rhabdomyolysis—Sorafenib—liver cancer	0.0118	0.0151	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—GSTA2—liver cancer	0.0118	0.075	CbGpPWpGaD
Melphalan—Skin necrosis—Epirubicin—liver cancer	0.0111	0.0141	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—AHR—liver cancer	0.0103	0.0655	CbGpPWpGaD
Melphalan—Skin necrosis—Doxorubicin—liver cancer	0.0102	0.0131	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—NFE2L2—liver cancer	0.01	0.0638	CbGpPWpGaD
Melphalan—Skin exfoliation—Sorafenib—liver cancer	0.00998	0.0128	CcSEcCtD
Melphalan—Neuropathy—Sorafenib—liver cancer	0.00981	0.0126	CcSEcCtD
Melphalan—Neoplasm—Sorafenib—liver cancer	0.00945	0.0121	CcSEcCtD
Melphalan—Mouth ulceration—Sorafenib—liver cancer	0.00945	0.0121	CcSEcCtD
Melphalan—Myelosuppression—Epirubicin—liver cancer	0.00823	0.0105	CcSEcCtD
Melphalan—Renal failure acute—Sorafenib—liver cancer	0.00822	0.0105	CcSEcCtD
Melphalan—Myelosuppression—Doxorubicin—liver cancer	0.00762	0.00975	CcSEcCtD
Melphalan—Hyponatraemia—Sorafenib—liver cancer	0.00762	0.00974	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—IL12B—liver cancer	0.00758	0.0484	CbGpPWpGaD
Melphalan—Local reaction—Epirubicin—liver cancer	0.00697	0.00892	CcSEcCtD
Melphalan—Local reaction—Doxorubicin—liver cancer	0.00645	0.00826	CcSEcCtD
Melphalan—Febrile neutropenia—Epirubicin—liver cancer	0.00642	0.00821	CcSEcCtD
Melphalan—Transaminases increased—Epirubicin—liver cancer	0.00635	0.00812	CcSEcCtD
Melphalan—Neutropenia—Sorafenib—liver cancer	0.00613	0.00784	CcSEcCtD
Melphalan—Febrile neutropenia—Doxorubicin—liver cancer	0.00594	0.0076	CcSEcCtD
Melphalan—Transaminases increased—Doxorubicin—liver cancer	0.00587	0.00751	CcSEcCtD
Melphalan—Neuropathy peripheral—Sorafenib—liver cancer	0.00573	0.00733	CcSEcCtD
Melphalan—Bone marrow depression—Epirubicin—liver cancer	0.00572	0.00732	CcSEcCtD
Melphalan—Stomatitis—Sorafenib—liver cancer	0.0057	0.00729	CcSEcCtD
Melphalan—Jaundice—Sorafenib—liver cancer	0.0057	0.00729	CcSEcCtD
Melphalan—Hepatobiliary disease—Sorafenib—liver cancer	0.00553	0.00707	CcSEcCtD
Melphalan—Bone marrow depression—Doxorubicin—liver cancer	0.00529	0.00677	CcSEcCtD
Melphalan—Haemoglobin—Sorafenib—liver cancer	0.00527	0.00675	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—CYP1A1—liver cancer	0.00525	0.0335	CbGpPWpGaD
Melphalan—Haemorrhage—Sorafenib—liver cancer	0.00525	0.00671	CcSEcCtD
Melphalan—Dermatitis atopic—Epirubicin—liver cancer	0.00522	0.00668	CcSEcCtD
Melphalan—Urinary tract disorder—Sorafenib—liver cancer	0.00518	0.00663	CcSEcCtD
Melphalan—Connective tissue disorder—Sorafenib—liver cancer	0.00516	0.0066	CcSEcCtD
Melphalan—Urethral disorder—Sorafenib—liver cancer	0.00514	0.00658	CcSEcCtD
Melphalan—Skin ulcer—Epirubicin—liver cancer	0.00496	0.00635	CcSEcCtD
Melphalan—Feeling hot—Epirubicin—liver cancer	0.00492	0.0063	CcSEcCtD
Melphalan—Flushing—Sorafenib—liver cancer	0.00487	0.00623	CcSEcCtD
Melphalan—Dermatitis atopic—Doxorubicin—liver cancer	0.00483	0.00618	CcSEcCtD
Melphalan—Immune system disorder—Sorafenib—liver cancer	0.00474	0.00606	CcSEcCtD
Melphalan—Mediastinal disorder—Sorafenib—liver cancer	0.00473	0.00605	CcSEcCtD
Melphalan—Arrhythmia—Sorafenib—liver cancer	0.00469	0.006	CcSEcCtD
Melphalan—Alopecia—Sorafenib—liver cancer	0.00464	0.00593	CcSEcCtD
Melphalan—Skin ulcer—Doxorubicin—liver cancer	0.00459	0.00587	CcSEcCtD
Melphalan—Feeling hot—Doxorubicin—liver cancer	0.00455	0.00582	CcSEcCtD
Melphalan—Neoplasm malignant—Epirubicin—liver cancer	0.00452	0.00579	CcSEcCtD
Melphalan—Extravasation—Epirubicin—liver cancer	0.00443	0.00566	CcSEcCtD
Melphalan—Amenorrhoea—Epirubicin—liver cancer	0.00439	0.00562	CcSEcCtD
Melphalan—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A2—liver cancer	0.00435	0.0278	CbGpPWpGaD
Melphalan—Anaemia—Sorafenib—liver cancer	0.00422	0.0054	CcSEcCtD
Melphalan—Neoplasm malignant—Doxorubicin—liver cancer	0.00418	0.00535	CcSEcCtD
Melphalan—Hyperuricaemia—Epirubicin—liver cancer	0.00416	0.00533	CcSEcCtD
Melphalan—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC40A1—liver cancer	0.00415	0.0265	CbGpPWpGaD
Melphalan—Extravasation—Doxorubicin—liver cancer	0.0041	0.00524	CcSEcCtD
Melphalan—Leukopenia—Sorafenib—liver cancer	0.00409	0.00523	CcSEcCtD
Melphalan—Ulcer—Epirubicin—liver cancer	0.00408	0.00522	CcSEcCtD
Melphalan—Amenorrhoea—Doxorubicin—liver cancer	0.00407	0.0052	CcSEcCtD
Melphalan—Cough—Sorafenib—liver cancer	0.00399	0.0051	CcSEcCtD
Melphalan—Blood uric acid increased—Epirubicin—liver cancer	0.00393	0.00503	CcSEcCtD
Melphalan—Myalgia—Sorafenib—liver cancer	0.00389	0.00498	CcSEcCtD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.00388	0.0248	CbGpPWpGaD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00386	0.00494	CcSEcCtD
Melphalan—Hepatocellular injury—Epirubicin—liver cancer	0.00386	0.00494	CcSEcCtD
Melphalan—SLC7A5—Transmembrane transport of small molecules—MYO5B—liver cancer	0.00385	0.0246	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.00385	0.0246	CbGpPWpGaD
Melphalan—Hyperuricaemia—Doxorubicin—liver cancer	0.00385	0.00493	CcSEcCtD
Melphalan—Injection site reaction—Epirubicin—liver cancer	0.00384	0.00491	CcSEcCtD
Melphalan—Ulcer—Doxorubicin—liver cancer	0.00378	0.00483	CcSEcCtD
Melphalan—Cystitis noninfective—Epirubicin—liver cancer	0.00377	0.00483	CcSEcCtD
Melphalan—Cystitis—Epirubicin—liver cancer	0.00373	0.00477	CcSEcCtD
Melphalan—Anaphylactic shock—Sorafenib—liver cancer	0.00373	0.00477	CcSEcCtD
Melphalan—Infection—Sorafenib—liver cancer	0.0037	0.00474	CcSEcCtD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.0037	0.0236	CbGpPWpGaD
Melphalan—Skin exfoliation—Epirubicin—liver cancer	0.00369	0.00472	CcSEcCtD
Melphalan—Thrombocytopenia—Sorafenib—liver cancer	0.00365	0.00467	CcSEcCtD
Melphalan—Blood uric acid increased—Doxorubicin—liver cancer	0.00364	0.00466	CcSEcCtD
Melphalan—Neuropathy—Epirubicin—liver cancer	0.00363	0.00464	CcSEcCtD
Melphalan—Skin disorder—Sorafenib—liver cancer	0.00362	0.00463	CcSEcCtD
Melphalan—Hepatocellular injury—Doxorubicin—liver cancer	0.00357	0.00457	CcSEcCtD
Melphalan—Anorexia—Sorafenib—liver cancer	0.00355	0.00455	CcSEcCtD
Melphalan—Injection site reaction—Doxorubicin—liver cancer	0.00355	0.00454	CcSEcCtD
Melphalan—Mouth ulceration—Epirubicin—liver cancer	0.00349	0.00447	CcSEcCtD
Melphalan—Bladder pain—Epirubicin—liver cancer	0.00349	0.00447	CcSEcCtD
Melphalan—Neoplasm—Epirubicin—liver cancer	0.00349	0.00447	CcSEcCtD
Melphalan—Cystitis noninfective—Doxorubicin—liver cancer	0.00349	0.00447	CcSEcCtD
Melphalan—Cystitis—Doxorubicin—liver cancer	0.00345	0.00441	CcSEcCtD
Melphalan—Skin exfoliation—Doxorubicin—liver cancer	0.00341	0.00436	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Sorafenib—liver cancer	0.0034	0.00435	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—HBE1—liver cancer	0.00337	0.0215	CbGpPWpGaD
Melphalan—Neuropathy—Doxorubicin—liver cancer	0.00335	0.00429	CcSEcCtD
Melphalan—Dyspnoea—Sorafenib—liver cancer	0.00332	0.00425	CcSEcCtD
Melphalan—Dyspepsia—Sorafenib—liver cancer	0.00328	0.0042	CcSEcCtD
Melphalan—Decreased appetite—Sorafenib—liver cancer	0.00324	0.00415	CcSEcCtD
Melphalan—Bladder pain—Doxorubicin—liver cancer	0.00323	0.00413	CcSEcCtD
Melphalan—Neoplasm—Doxorubicin—liver cancer	0.00323	0.00413	CcSEcCtD
Melphalan—Mouth ulceration—Doxorubicin—liver cancer	0.00323	0.00413	CcSEcCtD
Melphalan—Gastrointestinal disorder—Sorafenib—liver cancer	0.00322	0.00412	CcSEcCtD
Melphalan—Fatigue—Sorafenib—liver cancer	0.00321	0.00411	CcSEcCtD
Melphalan—Pain—Sorafenib—liver cancer	0.00319	0.00408	CcSEcCtD
Melphalan—Renal failure acute—Epirubicin—liver cancer	0.00304	0.00388	CcSEcCtD
Melphalan—Urticaria—Sorafenib—liver cancer	0.00296	0.00379	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—CDKN1B—liver cancer	0.00296	0.0189	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—IL2—liver cancer	0.0029	0.0185	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—JUN—liver cancer	0.00282	0.018	CbGpPWpGaD
Melphalan—Hyponatraemia—Epirubicin—liver cancer	0.00281	0.0036	CcSEcCtD
Melphalan—Renal failure acute—Doxorubicin—liver cancer	0.00281	0.00359	CcSEcCtD
Melphalan—Hypersensitivity—Sorafenib—liver cancer	0.00275	0.00351	CcSEcCtD
Melphalan—Asthenia—Sorafenib—liver cancer	0.00267	0.00342	CcSEcCtD
Melphalan—Cardiac arrest—Epirubicin—liver cancer	0.00267	0.00341	CcSEcCtD
Melphalan—Pruritus—Sorafenib—liver cancer	0.00264	0.00337	CcSEcCtD
Melphalan—Hyponatraemia—Doxorubicin—liver cancer	0.0026	0.00333	CcSEcCtD
Melphalan—Liver function test abnormal—Epirubicin—liver cancer	0.00259	0.00331	CcSEcCtD
Melphalan—Diarrhoea—Sorafenib—liver cancer	0.00255	0.00326	CcSEcCtD
Melphalan—Cardiac arrest—Doxorubicin—liver cancer	0.00247	0.00316	CcSEcCtD
Melphalan—Liver function test abnormal—Doxorubicin—liver cancer	0.00239	0.00306	CcSEcCtD
Melphalan—Vomiting—Sorafenib—liver cancer	0.00237	0.00303	CcSEcCtD
Melphalan—Rash—Sorafenib—liver cancer	0.00235	0.00301	CcSEcCtD
Melphalan—Dermatitis—Sorafenib—liver cancer	0.00235	0.003	CcSEcCtD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—F2—liver cancer	0.00233	0.0149	CbGpPWpGaD
Melphalan—Pancytopenia—Epirubicin—liver cancer	0.0023	0.00294	CcSEcCtD
Melphalan—Neutropenia—Epirubicin—liver cancer	0.00227	0.0029	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—TGFB1—liver cancer	0.00226	0.0144	CbGpPWpGaD
Melphalan—Nausea—Sorafenib—liver cancer	0.00221	0.00283	CcSEcCtD
Melphalan—Ibuprofen—PPARG—liver cancer	0.0022	0.0356	CrCbGaD
Melphalan—Pancytopenia—Doxorubicin—liver cancer	0.00213	0.00272	CcSEcCtD
Melphalan—Neuropathy peripheral—Epirubicin—liver cancer	0.00212	0.00271	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—TNF—liver cancer	0.00211	0.0135	CbGpPWpGaD
Melphalan—Stomatitis—Epirubicin—liver cancer	0.00211	0.00269	CcSEcCtD
Melphalan—Jaundice—Epirubicin—liver cancer	0.00211	0.00269	CcSEcCtD
Melphalan—Neutropenia—Doxorubicin—liver cancer	0.0021	0.00268	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—ANXA2—liver cancer	0.00208	0.0133	CbGpPWpGaD
Melphalan—Hepatobiliary disease—Epirubicin—liver cancer	0.00204	0.00261	CcSEcCtD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.00198	0.0126	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00197	0.0126	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—MYO5B—liver cancer	0.00196	0.0125	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.00196	0.0125	CbGpPWpGaD
Melphalan—Neuropathy peripheral—Doxorubicin—liver cancer	0.00196	0.00251	CcSEcCtD
Melphalan—Haemoglobin—Epirubicin—liver cancer	0.00195	0.00249	CcSEcCtD
Melphalan—Stomatitis—Doxorubicin—liver cancer	0.00195	0.00249	CcSEcCtD
Melphalan—Jaundice—Doxorubicin—liver cancer	0.00195	0.00249	CcSEcCtD
Melphalan—Haemorrhage—Epirubicin—liver cancer	0.00194	0.00248	CcSEcCtD
Melphalan—Hepatitis—Epirubicin—liver cancer	0.00194	0.00248	CcSEcCtD
Melphalan—Urinary tract disorder—Epirubicin—liver cancer	0.00192	0.00245	CcSEcCtD
Melphalan—Connective tissue disorder—Epirubicin—liver cancer	0.00191	0.00244	CcSEcCtD
Melphalan—Urethral disorder—Epirubicin—liver cancer	0.0019	0.00243	CcSEcCtD
Melphalan—Hepatobiliary disease—Doxorubicin—liver cancer	0.00189	0.00242	CcSEcCtD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.00189	0.012	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.00188	0.012	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ANXA2—liver cancer	0.0018	0.0115	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ATP7B—liver cancer	0.0018	0.0115	CbGpPWpGaD
Melphalan—Haemoglobin—Doxorubicin—liver cancer	0.0018	0.00231	CcSEcCtD
Melphalan—Flushing—Epirubicin—liver cancer	0.0018	0.0023	CcSEcCtD
Melphalan—Hepatitis—Doxorubicin—liver cancer	0.00179	0.0023	CcSEcCtD
Melphalan—Haemorrhage—Doxorubicin—liver cancer	0.00179	0.0023	CcSEcCtD
Melphalan—Urinary tract disorder—Doxorubicin—liver cancer	0.00177	0.00227	CcSEcCtD
Melphalan—Connective tissue disorder—Doxorubicin—liver cancer	0.00176	0.00226	CcSEcCtD
Melphalan—Urethral disorder—Doxorubicin—liver cancer	0.00176	0.00225	CcSEcCtD
Melphalan—Immune system disorder—Epirubicin—liver cancer	0.00175	0.00224	CcSEcCtD
Melphalan—Mediastinal disorder—Epirubicin—liver cancer	0.00175	0.00224	CcSEcCtD
Melphalan—Arrhythmia—Epirubicin—liver cancer	0.00173	0.00222	CcSEcCtD
Melphalan—Alopecia—Epirubicin—liver cancer	0.00171	0.00219	CcSEcCtD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—PIK3CB—liver cancer	0.00171	0.0109	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00171	0.0109	CbGpPWpGaD
Melphalan—Flushing—Doxorubicin—liver cancer	0.00167	0.00213	CcSEcCtD
Melphalan—Immune system disorder—Doxorubicin—liver cancer	0.00162	0.00207	CcSEcCtD
Melphalan—Mediastinal disorder—Doxorubicin—liver cancer	0.00162	0.00207	CcSEcCtD
Melphalan—Arrhythmia—Doxorubicin—liver cancer	0.0016	0.00205	CcSEcCtD
Melphalan—Alopecia—Doxorubicin—liver cancer	0.00159	0.00203	CcSEcCtD
Melphalan—Anaemia—Epirubicin—liver cancer	0.00156	0.002	CcSEcCtD
Melphalan—Leukopenia—Epirubicin—liver cancer	0.00151	0.00193	CcSEcCtD
Melphalan—Cough—Epirubicin—liver cancer	0.00147	0.00188	CcSEcCtD
Melphalan—Convulsion—Epirubicin—liver cancer	0.00146	0.00187	CcSEcCtD
Melphalan—Anaemia—Doxorubicin—liver cancer	0.00144	0.00185	CcSEcCtD
Melphalan—Chest pain—Epirubicin—liver cancer	0.00144	0.00184	CcSEcCtD
Melphalan—Myalgia—Epirubicin—liver cancer	0.00144	0.00184	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00143	0.00183	CcSEcCtD
Melphalan—Leukopenia—Doxorubicin—liver cancer	0.0014	0.00179	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—SERPINA1—liver cancer	0.00138	0.00881	CbGpPWpGaD
Melphalan—Anaphylactic shock—Epirubicin—liver cancer	0.00138	0.00176	CcSEcCtD
Melphalan—Oedema—Epirubicin—liver cancer	0.00138	0.00176	CcSEcCtD
Melphalan—Infection—Epirubicin—liver cancer	0.00137	0.00175	CcSEcCtD
Melphalan—Cough—Doxorubicin—liver cancer	0.00136	0.00174	CcSEcCtD
Melphalan—Convulsion—Doxorubicin—liver cancer	0.00135	0.00173	CcSEcCtD
Melphalan—Thrombocytopenia—Epirubicin—liver cancer	0.00135	0.00173	CcSEcCtD
Melphalan—Tachycardia—Epirubicin—liver cancer	0.00134	0.00172	CcSEcCtD
Melphalan—Skin disorder—Epirubicin—liver cancer	0.00134	0.00171	CcSEcCtD
Melphalan—Chest pain—Doxorubicin—liver cancer	0.00133	0.0017	CcSEcCtD
Melphalan—Myalgia—Doxorubicin—liver cancer	0.00133	0.0017	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00132	0.00169	CcSEcCtD
Melphalan—Anorexia—Epirubicin—liver cancer	0.00131	0.00168	CcSEcCtD
Melphalan—Hypotension—Epirubicin—liver cancer	0.00129	0.00165	CcSEcCtD
Melphalan—Oedema—Doxorubicin—liver cancer	0.00127	0.00163	CcSEcCtD
Melphalan—Anaphylactic shock—Doxorubicin—liver cancer	0.00127	0.00163	CcSEcCtD
Melphalan—Infection—Doxorubicin—liver cancer	0.00127	0.00162	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00126	0.00161	CcSEcCtD
Melphalan—Thrombocytopenia—Doxorubicin—liver cancer	0.00125	0.0016	CcSEcCtD
Melphalan—Tachycardia—Doxorubicin—liver cancer	0.00124	0.00159	CcSEcCtD
Melphalan—Skin disorder—Doxorubicin—liver cancer	0.00124	0.00158	CcSEcCtD
Melphalan—Paraesthesia—Epirubicin—liver cancer	0.00124	0.00158	CcSEcCtD
Melphalan—Dyspnoea—Epirubicin—liver cancer	0.00123	0.00157	CcSEcCtD
Melphalan—Anorexia—Doxorubicin—liver cancer	0.00122	0.00155	CcSEcCtD
Melphalan—Dyspepsia—Epirubicin—liver cancer	0.00121	0.00155	CcSEcCtD
Melphalan—Decreased appetite—Epirubicin—liver cancer	0.0012	0.00153	CcSEcCtD
Melphalan—Hypotension—Doxorubicin—liver cancer	0.00119	0.00152	CcSEcCtD
Melphalan—Gastrointestinal disorder—Epirubicin—liver cancer	0.00119	0.00152	CcSEcCtD
Melphalan—Fatigue—Epirubicin—liver cancer	0.00119	0.00152	CcSEcCtD
Melphalan—Pain—Epirubicin—liver cancer	0.00118	0.00151	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00116	0.00149	CcSEcCtD
Melphalan—Paraesthesia—Doxorubicin—liver cancer	0.00114	0.00146	CcSEcCtD
Melphalan—Dyspnoea—Doxorubicin—liver cancer	0.00114	0.00145	CcSEcCtD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—KRAS—liver cancer	0.00113	0.00723	CbGpPWpGaD
Melphalan—Dyspepsia—Doxorubicin—liver cancer	0.00112	0.00144	CcSEcCtD
Melphalan—Decreased appetite—Doxorubicin—liver cancer	0.00111	0.00142	CcSEcCtD
Melphalan—Gastrointestinal disorder—Doxorubicin—liver cancer	0.0011	0.00141	CcSEcCtD
Melphalan—Fatigue—Doxorubicin—liver cancer	0.0011	0.00141	CcSEcCtD
Melphalan—Urticaria—Epirubicin—liver cancer	0.00109	0.0014	CcSEcCtD
Melphalan—Pain—Doxorubicin—liver cancer	0.00109	0.00139	CcSEcCtD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—PIK3CA—liver cancer	0.00104	0.00664	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—IFNA1—liver cancer	0.00103	0.00656	CbGpPWpGaD
Melphalan—Hypersensitivity—Epirubicin—liver cancer	0.00102	0.0013	CcSEcCtD
Melphalan—Urticaria—Doxorubicin—liver cancer	0.00101	0.0013	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.001	0.00641	CbGpPWpGaD
Melphalan—Asthenia—Epirubicin—liver cancer	0.000988	0.00126	CcSEcCtD
Melphalan—Pruritus—Epirubicin—liver cancer	0.000975	0.00125	CcSEcCtD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—HRAS—liver cancer	0.000963	0.00615	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000959	0.00612	CbGpPWpGaD
Melphalan—Diarrhoea—Epirubicin—liver cancer	0.000943	0.00121	CcSEcCtD
Melphalan—Hypersensitivity—Doxorubicin—liver cancer	0.000939	0.0012	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000919	0.00586	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000919	0.00586	CbGpPWpGaD
Melphalan—Asthenia—Doxorubicin—liver cancer	0.000915	0.00117	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—PRKCE—liver cancer	0.000909	0.0058	CbGpPWpGaD
Melphalan—Pruritus—Doxorubicin—liver cancer	0.000902	0.00115	CcSEcCtD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—ALB—liver cancer	0.000893	0.0057	CbGpPWpGaD
Melphalan—Vomiting—Epirubicin—liver cancer	0.000876	0.00112	CcSEcCtD
Melphalan—Diarrhoea—Doxorubicin—liver cancer	0.000872	0.00112	CcSEcCtD
Melphalan—SLC7A5—Transmembrane transport of small molecules—CYCS—liver cancer	0.00087	0.00555	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000869	0.00555	CbGpPWpGaD
Melphalan—Rash—Epirubicin—liver cancer	0.000869	0.00111	CcSEcCtD
Melphalan—Dermatitis—Epirubicin—liver cancer	0.000868	0.00111	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—ABL1—liver cancer	0.000865	0.00552	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—IGF2—liver cancer	0.000862	0.0055	CbGpPWpGaD
Melphalan—Ibuprofen—ALB—liver cancer	0.000828	0.0134	CrCbGaD
Melphalan—Nausea—Epirubicin—liver cancer	0.000818	0.00105	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—HGF—liver cancer	0.000814	0.00519	CbGpPWpGaD
Melphalan—Vomiting—Doxorubicin—liver cancer	0.000811	0.00104	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—CSF2—liver cancer	0.000805	0.00513	CbGpPWpGaD
Melphalan—Rash—Doxorubicin—liver cancer	0.000804	0.00103	CcSEcCtD
Melphalan—Dermatitis—Doxorubicin—liver cancer	0.000803	0.00103	CcSEcCtD
Melphalan—Nausea—Doxorubicin—liver cancer	0.000757	0.000969	CcSEcCtD
Melphalan—SLC7A5—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000756	0.00482	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—UGDH—liver cancer	0.000697	0.00445	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—EPT1—liver cancer	0.000655	0.00418	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—MAPK14—liver cancer	0.000652	0.00416	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—F2—liver cancer	0.000631	0.00403	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—TAT—liver cancer	0.000621	0.00396	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—PPARA—liver cancer	0.000611	0.0039	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CG—liver cancer	0.000604	0.00386	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CD—liver cancer	0.000531	0.00339	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—SERPINE1—liver cancer	0.000525	0.00335	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—ALB—liver cancer	0.000524	0.00335	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—RAF1—liver cancer	0.000474	0.00303	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CB—liver cancer	0.000463	0.00295	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—ALB—liver cancer	0.000455	0.0029	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ALB—liver cancer	0.000454	0.0029	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—CYCS—liver cancer	0.000443	0.00283	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—IL2—liver cancer	0.000425	0.00271	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CPT1B—liver cancer	0.000422	0.00269	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GLUL—liver cancer	0.000422	0.00269	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—RAF1—liver cancer	0.00041	0.00262	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NR1H4—liver cancer	0.000407	0.0026	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTA3—liver cancer	0.0004	0.00255	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000385	0.00246	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTA4—liver cancer	0.000366	0.00234	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—VEGFA—liver cancer	0.000361	0.00231	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTA2—liver cancer	0.000357	0.00228	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTA1—liver cancer	0.000344	0.0022	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NAT2—liver cancer	0.00034	0.00217	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—TGFB1—liver cancer	0.000332	0.00212	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ALDOB—liver cancer	0.000326	0.00208	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CRABP1—liver cancer	0.000311	0.00199	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—PPARA—liver cancer	0.000311	0.00199	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—KRAS—liver cancer	0.000307	0.00196	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CA—liver cancer	0.000282	0.0018	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—TP53—liver cancer	0.000273	0.00174	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—HPGDS—liver cancer	0.000272	0.00174	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—HRAS—liver cancer	0.000261	0.00167	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PSMA4—liver cancer	0.000242	0.00155	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PSMD10—liver cancer	0.000242	0.00155	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GOT2—liver cancer	0.000236	0.0015	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ALB—liver cancer	0.000231	0.00148	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—AKT1—liver cancer	0.000231	0.00147	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP2E1—liver cancer	0.000222	0.00141	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—RAF1—liver cancer	0.000209	0.00133	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYCS—liver cancer	0.000207	0.00132	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GOT1—liver cancer	0.000204	0.0013	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GGT1—liver cancer	0.000204	0.0013	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTP1—liver cancer	0.000183	0.00117	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—HMOX1—liver cancer	0.00018	0.00115	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTM1—liver cancer	0.000168	0.00107	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP1A1—liver cancer	0.000159	0.00102	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—MTHFR—liver cancer	0.000149	0.000948	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PPARA—liver cancer	0.000146	0.00093	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CG—liver cancer	0.000125	0.000796	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PPARG—liver cancer	0.00012	0.000768	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CD—liver cancer	0.00011	0.0007	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ALB—liver cancer	0.000108	0.000691	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CB—liver cancer	9.56e-05	0.00061	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CA—liver cancer	5.83e-05	0.000372	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—AKT1—liver cancer	4.76e-05	0.000304	CbGpPWpGaD
